Blood, 1 May 2008, Vol. 111, No. 9, pp. 4471-4476.
Prepublished online as a Blood First Edition Paper on March 3, 2008; DOI 10.1182/blood-2007-11-123711.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based
Marcel Levi1,
G. Kees Hovingh1,
Suzanne C. Cannegieter2,
Marinus Vermeulen3,
Harry R. Büller1, and
Frits R. Rosendaal2
1 Department of Internal Medicine/Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam;
2 Department of Clinical Epidemiology, Leiden University Medical Center, Leiden; and
3 Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Vitamin K antagonists (VKAs) are effective antithrombotic agents and advocated in guidelines for the management of cardiovascular disease. However, in the trials underlying these guidelines, many patients were excluded. We performed a case-control study in 993 patients receiving VKAs, who required hospitalization for bleeding, and contrasted them to 993 matched control patients on VKAs, who were hospitalized for an infection. We analyzed whether patients and controls would have been eligible for the clinical trials on which their indication for anticoagulation was based, and estimated the risk of hemorrhage associated with exclusion criteria as applied in those trials. Approximately one quarter (23% [95% CI: 21%-26%]) of controls had one or more exclusion criteria for the trials, supporting the use of anticoagulation for their condition. Forty percent of patients presenting with bleeding had one or more exclusion criteria (95% CI: 37%-43%). Having one exclusion criterion resulted in a 2.9-fold increased risk of bleeding (95% CI: 2.2-3.9), and this risk increased sharply when more than one exclusion criterion was present. VKAs are often prescribed to patients who would not have qualified for clinical trials, and in these patients a careful consideration should be made regarding the expected efficacy and the risk of bleeding.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
|
